Abstracts tagged "outcomes"

Abstract Number: 2930 • 2015 ACR/ARHP Annual Meeting
Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events
Samar Alharbi¹, Jiandong Su², Stacey E. Morrison³, Mohammed Attar⁴, Khawla Al-Ghanim⁵, Murray Urowitz^6,7, Dafna Gladman² and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, University Health Network, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, TWH, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: To assess the impact of thrombotic events (TE) on 1) mortality, 2) SLE-related damage accrual; and 3) health-related quality of life (HRQoL) in patients…
Abstract Number: 1365 • 2014 ACR/ARHP Annual Meeting
ARE Erosions a Disappearing Feature in Rheumatoid Arthritis (RA)?Joint Damage in Patients with EARLY RA at 10 YEARS after Diagnosis
Juha Asikainen¹, Kalevi Kaarela², Heidi Mäkinen³, Hannu Kautiainen⁴, Pekka Hannonen⁵, Tuomas Rannio⁶ and Tuulikki Sokka¹, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Tampere University Hospital, Tampere, Finland, ⁴Medcare Oy, Äänekoski, Finland, ⁵Jyväskylä Central Hospital, Jyvaskyla, Finland, ⁶Kuopio University Hospital, Kuopio, Finland
Background/Purpose: Treatment of rheumatoid arthritis (RA) has improved during the last decade. Also importance of regular monitoring has been emphasized. Our objective was to study…
Abstract Number: 1256 • 2014 ACR/ARHP Annual Meeting
Clinical and Temporal Characterization of Anti-Jo-1 Positive Anti-Synthetase Syndrome: Preliminary Results of an International Multicentre Study
Lorenzo Cavagna¹, Miguel A González-Gay², Santos Castañeda-Sanz³, Franco Franceschini⁴, Paolo Airo⁵, Ilaria Cavazzana⁶, Laura Nuno⁷, Trinitario Pina Murcia², Francisco Javier Lopez Longo⁸, Norberto Ortego-Centeno⁹, Rossella Neri¹⁰, Simone Barsotti¹⁰, Enrico Fusaro¹¹, Simone Parisi¹², Giuseppe Paolazzi¹³, Giovanni Barausse¹³, Luca Quartuccio¹⁴, Elena Bartoloni-Bocci¹⁵, Carlo Selmi¹⁶, Carlo Alberto Scirè¹⁷, Elena Bravi¹⁸, Javier Bachiller Corral¹⁹, Lesley Ann Saketkoo²⁰, Gianluigi Bajocchi²¹, Raffaele Pellerito²², Marcello Govoni²³, Andreas Schwarting²⁴, Christof Specker²⁵, Carlomaurizio Montecucco¹ and Roberto Caporali²⁶, ¹Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario de La Princesa. Madrid. Spain, Madrid, Spain, ⁴AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, ⁵Rheumatology and Clinical Immunology, Spedali Civili, AO Spedali Civili, Brescia, Italy, ⁶Rheumatology and Clinical Immunology Unit, AO Spedali Civili, Brescia, Italy, ⁷Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁸Rheumatology, Hospital Gregorio Marañón. Madrid, Madrid, Spain, ⁹Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁰Rheumatology Unit, University of Pisa, Pisa, Italy, ¹¹Department of Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ¹²Rheumatology, Azienda Ospedaliera Città Della Salute e della Scienza, Turin, Italy, ¹³Rheumatology, Santa Chiara Hospital, Trento, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ¹⁵Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁶Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, ¹⁷Italian Society for Rheumatology, Milan, Italy, ¹⁸Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ¹⁹Rheumatology, Hospital Ramon y Cajal, Madrid, Spain, ²⁰Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²¹Department of Internal Medicine, Rheumatology Unit, Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy, ²²Rheumatology, Ospedale Mauriziano, Turin, Italy, ²³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ²⁴Rheumatology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁵Rheumazentrum Rhein-Ruhr e.V., St. Josef Krankenhaus (Kliniken Essen Süd), Universitätsklinikum Essen, Esssen, Germany, ²⁶Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose: anti Jo-1 antibodies are the main marker of the antisynthetase syndrome (As), a connective tissue disease chiefly characterized by arthritis (A), myositis (M) and…
Abstract Number: 1059 • 2014 ACR/ARHP Annual Meeting
Patients with RA from Wealthier Countries Perform Better on Clinical Disease Activity Measures, but Tend to Show Worse Person Reported Outcomes
Polina Putrik¹, Sofia Ramiro², Andras Keszei³, Ihsane Hmamouchi⁴, Maxime Dougados⁵, Monika Hifinger⁶, Laure Gossec⁷ and Annelies Boonen⁸, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ³Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ⁴Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁵Cochin Hospital, Paris Descartes University, Paris, France, ⁶Rheumatology, MUMC, University Hospital Maastricht, Maastricht, Netherlands, ⁷Rheumatology, Pierre et Marie Curie University, Paris, France, ⁸Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose Inequalities in health between low and high income countries are often reported, but it is not known whether clinical disease activity measures (“objective”) and…
Abstract Number: 811 • 2014 ACR/ARHP Annual Meeting
Biologics in Takayasu Arteritis: Preliminary Data from the French Registry
Arsene Mekinian¹, Chloe Comarmond², Mathieu Resche Regon³, Tristan Mirault⁴, Jean-Emmanuel Kahn⁵, Marc Lambert⁶, Jean Sibilia⁷, Antoine Neel⁸, Miguel Hié⁹, Emmanuel Messas¹⁰, Pascal Cohen¹¹, Geraldine Muller¹², Sabine Berthier¹³, Zahir Amoura¹⁴, Isabelle Marie¹⁵, Christian Lavigne¹⁶, Marie Anne Vandenhende¹⁷, Hervé Devilliers¹⁸, Sébastien Abad¹⁹, Loic Guillevin²⁰, Mohamed Hamidou²¹, Bertrand Godeau²², Patrice Cacoub²³, Olivier Fain²⁴ and David Saadoun², ¹DHU2iB, Internal Medicine Saint Antoine Hospital, PARIS, France, ²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ³biostatistics Saint Louis Hospital, paris, France, ⁴HEGP vascular department, paris, France, ⁵Internal Medicine, Foch Hospital, Suresnes, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁷Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁸INTERNAL MEDICINE, NANTES, France, ⁹Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹⁰HEGP hospital Vascular and cardiology Department, paris, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹²INTERNAL MEDICINE, DIJON, France, ¹³DIJON HOSPITAL, DIJON, France, ¹⁴Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹⁵CHU de Rouen, Rouen, France, ¹⁶CHU d'Angers, Angers, France, ¹⁷Internal Medicine, Bordeaux, France, ¹⁸Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ¹⁹Hôpital Avicenne, Bobigny, France, ²⁰Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, ²¹CHU Hôtel Dieu, Nantes, Nantes, France, ²²Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ²³Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²⁴Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France
Background/Purpose The aim of this registry is to determine: (1) the real-life use of various biological targeted treatments in Takayasu arteritis (TA) in France; (2)…
Abstract Number: 2903 • 2014 ACR/ARHP Annual Meeting
Early Outcomes in Pediatric Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)
Kimberly Morishita¹, Susanne Benseler², Rae S.M. Yeung³, Thomas Mason II⁴, Dawn Wahezi⁵, Kenneth N. Schikler⁶, Erica F. Lawson⁷, Susan Nielsen⁸, Sirirat Charuvanij⁹, Paul Dancey¹⁰, Susan Shenoi¹¹, Linda Wagner-Weiner¹², Angelyne Sarmiento¹, David A. Cabral¹³ and For the PedVas Initiative¹, ¹BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology - Department of Medicine, Mayo Clinic, Rochester, MN, ⁵Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁶Department of Pediatrics, Univ of Louisville Schl of Med, Louisville, KY, ⁷Pediatrics, University of California, San Francisco, San Francisco, CA, ⁸Pediatric rheumatology, Rigshospitalet, Copenhagen, Denmark, ⁹Pediatrics, Siriraj Hospital, Bangkok, Thailand, ¹⁰Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ¹¹Pediatric Rheumatology, Seattle Childrens Hospital, seattle, WA, ¹²Pediatric Rheumatology, University of Chicago Hospital, Chicago, IL, ¹³Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Childhood AAV is rare and outcome studies are limited. The PedVas Study is an international initiative collecting clinical data (to A Registry of Childhood…
Abstract Number: 813 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcomes of Takayasu’s Arteritis Patients with Renal Artery Involvement
Corisande Baldwin¹, Aladdin Mohammad² and David Jayne³, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Dept. of Rheumatology, Lund University Hospital, Lund University, Lund, Lund, Sweden, ³Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Takayasu's Arteritis (TAK) is a chronic inflammatory large vessel vasculitis characterized by granulomatous inflammation of the aorta and its branches. TAK incidence is 2.6/million…
Abstract Number: 2911 • 2014 ACR/ARHP Annual Meeting
Clinical Outcomes of Early RA after 7 Years – Does T2T Approach Overcome Delay of Therapy?
Tuulikki Sokka¹, Hannu Kautiainen², Tuomas Rannio³, Juha Asikainen¹ and Pekka Hannonen¹, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Medcare Oy, Äänekoski, Finland, ³Kuopio University Hospital, Kuopio, Finland
Background/Purpose: Early vs. delayed referral/start of therapy within 3-4 months has been shown beneficial for outcomes in rheumatoid arthritis (RA) (Lard et al. AM J…
Abstract Number: 685 • 2014 ACR/ARHP Annual Meeting
Successful Withdrawal and Discontinuation of Immunosuppressants in Lupus Patients: Outcomes and Predictors
Zahi Touma¹, Murray B. Urowitz², Dominique Ibanez¹ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Physicians and patients (Pts) are hesitant to withdraw immunosuppressant (IS) in Pts in clinical remission as the consequences of this approach are unknown.…
Abstract Number: 2812 • 2014 ACR/ARHP Annual Meeting
Is Rheumatoid Arthritis the Same Disease in Women and Men?- Joint Damage in Patients with EARLY Rheumatoid Arthritis at 10 YEARS after Diagnosis
Juha Asikainen¹, Kalevi Kaarela², Heidi Mäkinen³, Hannu Kautiainen⁴, Pekka Hannonen⁵, Tuomas Rannio⁶ and Tuulikki Sokka⁷, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Tampere University Hospital, Tampere, Finland, ⁴Medcare Oy, Äänekoski, Finland, ⁵Jyväskylä Central Hospital, Jyvaskyla, Finland, ⁶Kuopio University Hospital, Kuopio, Finland, ⁷Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatoid arthritis (RA) is suggested to be a more severe disease in women than in men as disease activity appears higher in women, and…
Abstract Number: 573 • 2014 ACR/ARHP Annual Meeting
Three-Year Course and Prediction of Physical Functioning in Ankylosing Spondylitis Patients Treated with TNF-Inhibitors
Salima F.E. van Weely¹, Eva L. Kneepkens¹, Mike T. Nurmohamed¹, Joost Dekker^1,2 and Irene E. van der Horst-Bruinsma³, ¹Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, ²Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ³Rheumatology, VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Currently, only limited information is available on the long-term course of limitations in physical functioning and spinal mobility in Ankylosing Spondylitis (AS) patients receiving…
Abstract Number: 2786 • 2014 ACR/ARHP Annual Meeting
Aortitis: Outcomes from a Cohort of 196 Patients
Alison Clifford¹, Amr Arafat², Jahanzaib Idrees², Eric Roselli², Carmela D. Tan³, E. Rene Rodriguez³, Lars Svensson², Eugene Blackstone² and Gary S. Hoffman¹, ¹Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ²Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, ³Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Idiopathic aortitis is a rare diagnosis that may occur in the context of a primary systemic vasculitis, as part of a systemic autoimmune disease,…
Abstract Number: 546 • 2014 ACR/ARHP Annual Meeting
Psoriatic Arthritis Mutilans: Characteristics and Radiographic Progression
Deepak R. Jadon¹, Gavin Shaddick², William Tillett¹, Graham Robinson³, Charlotte Cavill¹, Nicola Waldron¹, Eleanor Korendowych¹ and Neil J McHugh⁴, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Royal United Hospital, Bath, United Kingdom, ⁴Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Psoriatic arthritis mutilans (PAM) is a rare extreme subtype of psoriatic arthritis (PsA). Our objectives were to: (1) compare clinical characteristics of PsA patients…
Abstract Number: 2626 • 2014 ACR/ARHP Annual Meeting
Relationship of Socio-Demographic and Disease Factors with Loss-to-Follow-up and Appointment Noncompliance in Indigent Patients with Systemic Lupus Erythematosus
Angela Pham¹, Gaobin Bao², S. Sam Lim³ and Cristina Drenkard⁴, ¹Rheumatology, Emory University, Atlanta, GA, ²Medicine, Emory University, Atlanta, GA, ³Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ⁴Medicine, Div Rheumatology, Emory University, Atlanta, GA
Background/Purpose . The relationship of medical noncompliance with poor health outcomes has been described in chronic diseases, including systemic lupus erythematosus (SLE). These outcomes are…
Abstract Number: 382 • 2014 ACR/ARHP Annual Meeting
What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months?
Edward C. Keystone¹, Carter Thorne², Michael Starr³, Jude Rodrigues⁴, Philip Baer⁵, Regan Arendse⁶, J. Antonio Avina-Zubieta⁷, Denis Choquette⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, May Shawi¹⁰, Francois Nantel¹⁰, Allen J Lehman¹¹ and Susan Otawa¹¹, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁵Private Practice, Scarborough, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to optimize symptom control and, when possible, achieve sustained remission. Therefore, identification of clinical signs predicting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].